Stock 603739 QINGDAO VLAND BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Qingdao Vland Biotech INC.

Equities

603739

CNE100003GX8

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
11.46 CNY +9.98% Intraday chart for Qingdao Vland Biotech INC. +18.14% -24.70%
Apr. 25 Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 25 Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Capitalization 1 3,474 4,689 3,387 3,851 2,900 -
Enterprise Value (EV) 1 3,474 4,689 3,387 3,851 2,900 2,900
P/E ratio 22.9 x 34.4 x 49.7 x 47.6 x 21 x 18.2 x
Yield - 0.86% 0.75% 0.66% 1.66% 2.01%
Capitalization / Revenue 3.62 x 4.07 x 2.91 x 3.21 x 2.01 x 1.78 x
EV / Revenue 3.62 x 4.07 x 2.91 x 3.21 x 2.01 x 1.78 x
EV / EBITDA - - - 19.5 x 8.33 x 6.65 x
EV / FCF - -11,607,096 x -13,735,839 x - - -
FCF Yield - -0% -0% - - -
Price to Book - 2.92 x 2.06 x 2.25 x 1.61 x 1.51 x
Nbr of stocks (in thousands) 216,534 252,085 252,412 253,029 253,029 -
Reference price 2 16.04 18.60 13.42 15.22 11.46 11.46
Announcement Date 4/20/21 4/19/22 4/26/23 4/25/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net sales 1 960.2 1,151 1,163 1,199 1,440 1,626
EBITDA 1 - - - 197.2 348 436
EBIT 1 - 170.9 102.9 122.9 192.5 225.5
Operating Margin - 14.85% 8.85% 10.25% 13.37% 13.86%
Earnings before Tax (EBT) 1 - 171.4 102.2 122.5 192.5 225
Net income 1 - 132.6 69.84 80.71 137.5 160
Net margin - 11.52% 6% 6.73% 9.55% 9.84%
EPS 2 0.7000 0.5400 0.2700 0.3200 0.5450 0.6300
Free Cash Flow - -404 -246.6 - - -
FCF margin - -35.1% -21.2% - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 - 0.1600 0.1000 0.1000 0.1900 0.2300
Announcement Date 4/20/21 4/19/22 4/26/23 4/25/24 - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - -404 -247 - - -
ROE (net income / shareholders' equity) - 9.42% 4.3% 4.82% 7.37% 8.04%
ROA (Net income/ Total Assets) - - - - 4.03% 4.44%
Assets 1 - - - - 3,412 3,604
Book Value Per Share 2 - 6.370 6.520 6.750 7.140 7.570
Cash Flow per Share 2 - - 0.3800 0.6100 0.9700 1.150
Capex 1 - 493 342 215 224 247
Capex / Sales - 42.88% 29.4% 17.91% 15.52% 15.16%
Announcement Date 4/20/21 4/19/22 4/26/23 4/25/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Qingdao Vland Biotech INC.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.46
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
QINGDAO VLAND BIOTECH INC. Stock Qingdao Vland Biotech INC.
-24.70% 400M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 603739 Stock
  4. Financials Qingdao Vland Biotech INC.